MEI Pharma Inc Shares Close the Week 21.8% Lower - Weekly Wrap
The company saw its shares close the week 21.8% lower than last week, with trading volume higher than its 30 day average.
May 14, 2021 by Kwhen Finance Editors
MEI Pharma Inc (MEIP) shares closed this week 21.8% lower than it did at the end of last week. The stock is currently down 1.7% year-to-date, down 8.3% over the past 12 months, and up 84.0% over the past five years. This week, the Dow Jones Industrial Average fell 1.5%, and the S&P 500 fell 2.1%.
Trading Activity
- Shares traded as high as $3.56 and as low as $2.57 this week.
- Shares closed 4e+1% below its 52-week high and 2e+1% above its 52-week low.
- Trading volume this week was 155.0% higher than the 10-day average and 230.6% higher than the 30-day average.
- Beta, a measure of the stock’s volatility relative to the overall market stands at 0.8.
Technical Indicators
- The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.
- MACD, a trend-following momentum indicator, indicates a downward trend.
- The stock closed below its Bollinger band, indicating it may be oversold.
Fundamentals & Catalysts
- Over the past 12 months the company generated $-34,403,000 in earnings before interest and taxes from $39 million in revenue. It currently holds $180 million in cash and $37 million in debt.
- Its forward price-to-earnings (P/E) ratio of -7.687927236494955 is lower than its current P/E ratio of -4.61, implying that analysts are expecting an increase in earnings.
- The company's price/earnings-to-growth ratio (PEG Ratio), a widely used indicator of a stock's true value while also factoring in expected earnings growth, currently stands at -0.33. A fairly valued company should have a PEG ratio of 1.0. When a company's PEG exceeds 1.0, it's considered overvalued while a stock with a PEG of less than 1.0 is considered undervalued.
- The company's debt-to-equity ratio, which measures the extent to which it finances its operations through debt, currently stands at 2.77 which means it currently has $2.77 of debt for every $1 of equity. Generally speaking, a debt to equity ratio below 1.0 is seen as relatively safe, while ratios of 2.0 or higher would be considered risky. Some industries are known for having much higher debt to equity ratios than others.
- The company's price-to-book ratio, which measures the market's valuation of a company relative to its book value, currently stands at 5.74. This means that the stock is trading at a premium of 6 times relative to the company's book value which reflects the total value of a company's assets that shareholders of that company would receive if the company were to be liquidated.
- The company's price-to-sales ratio, which shows how much the market values every dollar of the company's sales, currently stands at 10.62.
- The company's enterprise value-to-revenue multiple, which is often used to determine a company's valuation in the case of a potential acquisition, currently stands at 6.08.
P/E
-4.61
EBITDA
$-34,403,000
P/Book
5.74
Mkt Cap
$292M
P/Sales
10.62
Revenue
$39M
EPS (TTM)
-0.57
PEG Ratio
-0.33
EV/Revenue
6.08
Total Cash
$180M
Debt/Equity
2.77
Forward P/E
-7.69
Current Debt
$37M
Gross Profit
$37M
Dividend Date
-
Earnings Date
-
Profit Margin
-0.91
Revenue/Share
0.35
Total Revenue
$39M
Enterprise Val
$241M
Put/Call Ratio
0.40
Revenue/Employee
0.00
Market Comparative Performance
- The company's share price lags the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis
- The company's share price lags the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis
- The company share price lags the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and lags it on a 5 year basis
| Name | DoD %Δ | YTD %Δ | 1 Yr % | 52-Week H % | 52-Week L % |
|---|---|---|---|---|---|
| MEI Pharma Inc | 6.4 | -1.7 | -8.3 | -43.2 | 13.5 |
| Dow Jones Industrial Average | 1.1 | 11.9 | 49.1 | -2.5 | 49.3 |
| S&P 500 Index | 1.5 | 10.1 | 48.0 | -2.3 | 49.2 |
| Health Care | 0.9 | 7.3 | 25.7 | -1.6 | 30.1 |
Peer Group Comparative Performance
- The company's stock price performance year-to-date lags the peer average by -121.4%
- The company's stock price performance over the past 12 months lags the peer average by -104.1%
| Name | MKT CAP (USD) | P/E | YTD %Δ | 1 Yr %Δ | 52-Week H % | 52-Week L % |
|---|---|---|---|---|---|---|
| MEI Pharma Inc | MEIP | -4.6 | -1.7 | -8.3 | -43.2 | 13.5 |
| Peer Avg | N/A | 7.9 | 8.0 | 203.4 | -44.3 | 261.2 |
| Ligand Pharmaceuticals, Inc. - Class B | LGND | 52.6 | 24.6 | 26.0 | -43.1 | 59.6 |
| Array Technologies Inc | ARRY | 0 | -66.5 | -60.4 | -73.7 | 9.1 |
| Curis Inc | CRIS | -40.0 | 59.6 | 1624.3 | -23.7 | 1726.0 |
| XOMA Corp | XOMA | 58.4 | -33.6 | 43.0 | -36.8 | 89.1 |
| Galectin Therapeutics Inc | GALT | 0 | 87.9 | 58.3 | -24.9 | 135.2 |
| Heat Biologics Inc | HTBX | 0 | 7.8 | 43.6 | -80.5 | 49.5 |
| Onconova Therapeutics Inc | ONTX | 0 | 7.9 | 40.6 | -73.3 | 171.2 |
| Cyclacel Pharmaceuticals Inc | CYCC | 0 | -16.0 | 55.5 | -42.3 | 111.2 |
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2021 Kwhen Inc.
Was this content valuable for you?
Tags: